Do These Sequence Analysis Method Patents Satisfy Section 101?
By EsqSocial Corporation 07/02/14
According to an article on Law360, Bristol-Myers Squibb Co. is challenging the validity of two Genetic Technologies Ltd. patents on the basis that the claimed intron sequence analysis methods recite natural phenomena that do not satisfy the...
By: Foley & Lardner LLP